CardiologyOnline.net

Cardiology Xagena

In the ENGAGE AF-TIMI 48 trial, the higher-dose Edoxaban ( HDE; Lixiana, Savaysa ) regimen had a similar incidence of ischaemic stroke compared with Warfarin ( Coumadin ), whereas a higher incidence w ...


In patients with persistent atrial fibrillation ( AF ), the sinus rhythm ( SR ) can be restored by direct current cardioversion ( DCC ), although the recurrence of atrial fibrillation after successful ...


Transcatheter aortic valve implantation ( TAVI ) is a therapeutic treatment for patients with severe aortic stenosis ( AS ) at high surgical risk. Although the procedure is associated with a reducti ...


Emerging clinical evidence demonstrates high prevalence of QTc prolongation and complex ventricular arrhythmias in patients with anti-Ro antibody ( anti-Ro Ab ) positive autoimmune diseases. Resea ...


Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk ...


Recent trials have shown a reduction in the risk of major adverse cardiac events ( MACE ) with Simvastatin and Ezetimibe ( Vytorin ) therapy in patients with acute coronary syndrome. The potential be ...


The effect of LCZ696 on blood pressure was evaluated in patients with heart failure with preserved ejection fraction ( HFpEF ) in the PARAMOUNT ( Prospective comparison of ARNI with ARB on Management ...


Patients with a high-risk Paclitaxel drug-eluting stent who were given the shorter-acting antiplatelet drug Cilostazol ( Pletal ) prior to a surgical procedure safely transitioned off of dual antiplat ...


A 8-week, multicenter, open-label study has assessed the safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dys ...


Heart failure and dementia frequently coexist, but little is known about their types, relationships to each other and prognosis. The aims of this study were to (i) describe patients with heart failu ...


Catheter ablation of atrial fibrillation is an established therapy for symptomatic patients. The long-term efficacy and impact of catheter ablation among patients with severe systolic heart failure re ...


Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors ( ACEi ) and angiotensin receptor blockers ( ARBs; sarta ...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk of stroke for patients with non-valvular atrial fibrillation ( NVAF ) w ...


The recent availability of Dabigatran ( Pradaxa ), a novel oral anticoagulant, provided a new treatment option for stroke prevention in atrial fibrillation beyond Warfarin ( Coumadin ), the main thera ...


The new oral anticoagulants ( NOACs ) Dabigatran etexilate ( Pradaxa ), Rivaroxaban ( Xarelto ), and Apixaban ( Eliquis ) show similar efficacy for stroke prevention in patients with atrial fibrillati ...


Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation frequently recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent r ...


Two separate clinical trials were presented as a part of ACC.15, and looked at strategies to reduce major bleeding and mortality in patients with acute coronary syndrome ( ACS ). Both trials are part ...


Patients taking Digoxin ( Lanoxin ) to control atrial fibrillation face a 27% greater risk of dying than atrial fibrillation patients who are not taking digoxin, according to an analysis of 19 studies ...


The FDA ( Food and Drug Administration ) has expanded the approved use of the CoreValve System to treat certain patients who have previously had a tissue aortic valve replacement and are in need of a ...


The important factor for efficacy and safety for patients with atrial fibrillation undergoing electrical cardioversion ( ECV ) is appropriate use of oral anticoagulant ( OAC ) therapy. Dabigatran ( ...


Current guidelines do not explicitly recommend statin use in heart failure ( HF ). Relatively low numbers of atherothrombotic events among patients with heart failure, in the context of their elevated ...


New detailed data from the phase 3 YUKAWA-2 study evaluating Evolocumab ( Repatha ), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and hig ...


New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vit ...


Researchers have examined the influence of catheter ablation ( CA ) and peri-procedural anticoagulation regimen on trajectory of migraine in atrial fibrillation patients with or without migraine-histo ...


Thiazide diuretics are recommended as first-line therapy for hypertension and are among the most commonly prescribed drugs worldwide. According to their molecular structure, thiazide diuretics can b ...


The FDA ( Food and Drug Administration ) has approved the ResQCPR System, a system of two devices for first responders to use while performing cardiopulmonary resuscitation ( CPR ) on people with card ...


A study has examined the efficacy and bleeding outcomes of Cangrelor ( Kengrexal ) in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects ...


Intravenous ( IV ) Morphine has been shown to be independently associated with adverse clinical outcome in patients with non-STEMI. Currently, there are no data on the association of IV Morphine and r ...


Researchers have investigated the risk for recurrent coronary events associated with insulin resistance in post infarction patients from the Thrombogenic Factors and Recurrent Coronary Events ( THROMB ...


Currently available antiarrhythmic agents for the treatment of atrial fibrillation have important limitations, leaving an unmet need for safe and effective therapy. Ranolazine is an approved antiang ...


Dronedarone ( Multaq ) is a benzofuran derivative with a pharmacological profile similar to Amiodarone but has a more rapid onset of action and a much shorter half-life ( 13-19 h ). Researchers ha ...


With the introduction of novel oral anticoagulants ( NOACs ), the factors driving anticoagulant selection in atrial fibrillation ( AF ) in real-world practice are unclear. The goal was to examine ...


European Xarelto ( Rivaroxaban ) product information has now included guidance for use in patients with atrial fibrillation undergoing cardioversion. The label update is based on findings from the ...


A study has assessed the effect of Ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial fibrillation in acute coronary syndromes ( ACS ) and has determi ...


A study has tested the hypothesis that chocolate consumption is associated with a lower risk of heart failure. Researchers prospectively studied 20 278 men from the Physicians' Health Study ( PHS ) ...


A study has evaluated the long-term response and safety of interleukin-1 receptor antagonist, Anakinra ( Kineret ) in recurrent pericarditis. Fifteen patients ( 12 children, 3 adults ) were enrolle ...


At the end of two previous trials, an excess of stroke and bleeding was observed in patients with atrial fibrillation randomized to a new oral anticoagulant ( NOAC ) who transitioned to a vitamin K an ...


Deficient nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signaling results from endothelial dysfunction and may underlie impaired cardiac relaxation in patients with heart failu ...


The IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine Vytorin ( Ezetimibe / Simvastatin ), which com ...


Morphine is recommended in patients with ST-segment-elevation myocardial infarction, including those undergoing primary percutaneous coronary intervention ( PCI ). Suboptimal antiplatelet effect durin ...


X-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients with atrial fibrillation undergoing elective cardioversion. Researchers have assigned 1504 patients to Riv ...


Evidence is conflicting with regards to the role of vitamin D in statin induced myalgia ( SIM ). Studies so far have assessed cross-sectional association and were limited by study sample selected pred ...


The value of Aspirin ( Acetylsalicylic acid ) in primary prevention of cancer and cardiovascular disease ( CVD ) remains unclear. The aim of a study was to identify women who benefit from alternate- ...


It was hypothesized that in patients with stable coronary artery disease and stenosis, percutaneous coronary intervention ( PCI ) performed on the basis of the fractional flow reserve ( FFR ) would be ...


Ischemic mitral regurgitation is associated with increased mortality and morbidity. For surgical patients with moderate regurgitation, the benefits of adding mitral-valve repair to coronary-artery byp ...


The aim of a study was to evaluate the population pharmacokinetics ( PK ) and exposure-response relationship of Edoxaban ( Lixiana, Savaysa ) in patients with non-valvular atrial fibrillation ( AF ). ...


Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. Patients were enrolled aft ...


Atrial fibrillation and heart failure often coexist, causing substantial cardiovascular morbidity and mortality. Beta-blockers are indicated in patients with symptomatic heart failure with reduced eje ...


Little is known in clinical practice about antiarrhythmic drugs ( AADs ) use in patients with atrial fibrillation ( particularly younger ones ) who do not have structural heart disease. Using the ...


Dronedarone ( Multaq ) is a non-iodinated benzofuran derivative with antiarrhythmic properties. In placebo-controlled atrial fibrillation trials, the drug was found to have divergent effects on endpoi ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati